AI-Driven Genomics
for Pharma

We Deliver Profound Insight into the
Genetic Drivers of Disease

Pharma companies need comprehensive genomic information to drive successful precision medicine programs, but decisions are often made using only a fraction of the data available…about 10%.
Genomenon delivers 100% of the data.

LATEST WEBINAR WITH INOZYME PHARMA
Locus-Specific Patient Databases for Rare Disease:
A Computational Approach

Patient Landscapes Enrich Natural History Studies


An efficient and cost-effective natural history research solution for Pharma, Genomenon Patient Landscapes support the development of rare disease therapies by enhancing insights contained in retrospective and prospective health data. Using a powerful AI-driven approach, Genomenon delivers comprehensive and expert assessment of every patient in the published medical literature – in a fraction of the time.


READ MORE
Patient Landscapes Enrich Natural History Studies

ARTICLE | Comprehensive Genomic Landscape for ALS
Read the latest article in the Journal of Precision Medicine revealing the clinical and genetic complexity of ALS.

5X More Variants in Weeks

Genomenon identified all of the genomic drivers in TARDBP associated with ALS in just two weeks…a yield of 435% more than the number of disease-causing variants found in ClinVar


Comprehensive

Don’t miss anything – get insight into every genomic biomarker published in the medical literature

Evidence-Based

Every scientific assertion is supported by empirical evidence from the medical literature

5X More Variants in Weeks

NEW REPORT: Key Findings from the Genomic Landscape for ALS Discover profound insights from Genomenon’s comprehensive Genomic Landscape for ALS, and their impact on Pharma

De-Risk Your Precision Medicine Program

UNCOVER

3-10X MORE TARGETS

Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards

GAIN INSIGHT

INTO DISEASE MECHANISM

Better understand the role of pathogenic variants and their functional consequence on disease presentation, backed by evidence

IDENTIFY

MORE OF THE RIGHT PATIENTS

Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards

DE-RISK

CLINICAL TRIAL OUTCOMES

De-risk your precision medicine program by applying the genetic knowledge gained by working with Genomenon

Learn how a leading rare disease pharma company leveraged genomics to target their clinical trials.

Genomenon Genomic Landscapes provide the complete picture of a disease or pathway with a unique 2-pronged approach

Robot-Human-Cyborg 2020-robot

AI-Driven

Genomenon’s Computational Intelligence organizes and indexes all medical evidence and makes it easily searchable

Robot-Human-Cyborg 2020-human

Expertly Curated

Genomenon’s Experts assess the variants for clinical effect, score for pathogenicity, and review to ensure data quality

ALS GENOMIC LANDSCAPE NOW AVAILABLE!

Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.


<h5>Vice President, Translational Research & Development,  Rare Disease Pharmaceutical Company<h5>
Vice President, Translational Research & Development, Rare Disease Pharmaceutical Company

Genomenon’s methodology improved the efficiency and completeness of our literature review process.


<h5>Vice President, Translational Research & Development,  Rare Disease Pharmaceutical Company<h5>
Vice President, Translational Research & Development, Rare Disease Pharmaceutical Company

EXPLORE OUR FULL CAPABILITIES FOR PHARMA